Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-DENV-2 Envelope protein E Polyclonal Antibody

Catalog #:   PVV19906 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: P29990
Overview

Catalog No.

PVV19906

Species reactivity

Dengue virus type 2 (strain Thailand/16681/1984) (DENV-2)

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant DENV-2 Envelope protein E (Met281-Ala722).

Tested applications

ELISA: 1:4000-1:8000, WB: 1:1000-1:4000

Target

Genome polyprotein, Capsid protein C, Core protein, Protein prM, Peptide pr, Small envelope protein M, Matrix protein, Envelope protein E, Non-structural protein 1, NS1, Non-structural protein 2A, NS2A, Serine protease subunit NS2B, Flavivirin protease NS2B regulatory subunit, Non-structural protein 2B, Serine protease NS3, 3.4.21.91, 3.6.1.15, 3.6.4.13, Flavivirin protease NS3 catalytic subunit, Non-structural protein 3, Non-structural protein 4A, NS4A, Peptide 2k, Non-structural protein 4B, NS4B, RNA-directed RNA polymerase NS5, 2.1.1.56, 2.1.1.57, 2.7.7.48, Non-structural protein 5

Purification

Purified by antigen affinity column.

Accession

P29990

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with Envelope protein E antibody (PVV19906) at 1 µg/ml.

    Lane 1: Recombinant Protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 51 kDa
    Observed MW: 51 kDa
References

Seropositivity to Dengue, Zika, Yellow Fever, and West Nile Viruses in Senegal, West Africa., PMID:40207881

miRNome analysis reveals mir-155-5p as a protective factor to dengue infection in a resistant Thai cohort., PMID:39976655

Genetic diversity of dengue virus circulating in the Philippines (2014-2019) and comparison with dengue vaccine strains., PMID:39700304

Dominance of dengue virus serotype-2 in Pakistan (2023-2024): Molecular characterization of the envelope gene and exploration of antiviral targets., PMID:39557198

Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil., PMID:39116904

Epidemiological, virological and clinical characterization of a Dengue/Zika outbreak in the Caribbean region of Costa Rica 2017-2018., PMID:38988809

Development of optical and electrochemical immunodevices for dengue virus detection., PMID:38780022

Low-temperature culture enhances production of flavivirus virus-like particles in mammalian cells., PMID:38416210

Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults., PMID:38294972

Clinical, Virological, and Immunological Features in Cosmopolitan Genotype DENV-2-Infected Patients during a Large Dengue Outbreak in Sri Lanka in 2017., PMID:37696512

Epitope prediction and designing of receptor inhibitor of Dengue Envelope Protein: An in silico approach., PMID:37417165

Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody., PMID:37409936

Evolutionary dynamics of dengue virus in India., PMID:37011104

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study., PMID:36888687

Efficient generation and characterization of chimeric dengue viral-like particles., PMID:36878035

Evaluation of an Immunoglobulin E Capture Enzyme-Linked Immunosorbent Assay for the Early Diagnosis of Dengue., PMID:36862827

The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature., PMID:36734144

Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus., PMID:36723792

Reactivity of DENV-positive sera against recombinant envelope proteins produced in bacteria and eukaryotic cells., PMID:36192522

Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages., PMID:35596058

Sulfated β-glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis., PMID:35533778

Differential heterologous neutralisation profile against strains within DENV-3 genotype II., PMID:35225194

In-vitro antiviral action of Eupatorium perfoliatum against dengue virus infection: Modulation of mTOR signaling and autophagy., PMID:34509603

In Vitro Antiviral Activity of α-Mangostin against Dengue Virus Serotype-2 (DENV-2)., PMID:34069351

Co-Circulation of All Four Dengue Viruses and Zika Virus in Guerrero, Mexico, 2019., PMID:33944623

Generation and characterization of luciferase-secreting, single-round infectious DENV-2 reporter for functional antibody assays., PMID:33662412

Chimeric flavivirus enables evaluation of antibodies against dengue virus envelope protein in vitro and in vivo., PMID:33299049

DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model., PMID:33121347

Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan., PMID:32866533

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement., PMID:32305868

Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine., PMID:32300346

Aedes aegypti lachesin protein binds to the domain III of envelop protein of Dengue virus-2 and inhibits viral replication., PMID:32141690

Alanine Substitution Inactivates Cross-Reacting Epitopes in Dengue Virus Recombinant Envelope Proteins., PMID:32069839

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor., PMID:32015557

The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study., PMID:30934772

Dynamics of nonstructural glycoprotein-1 in dengue patients presenting with different clinical manifestations from 1986 to 2012 in Rio de Janeiro, Brazil., PMID:30411369

Surveillance for Flaviviruses Near the Mexico-U.S. Border: Co-circulation of Dengue Virus Serotypes 1, 2, and 3 and West Nile Virus in Tamaulipas, Northern Mexico, 2014-2016., PMID:30226141

Establishment of Baculovirus-Expressed VLPs Induced Syncytial Formation Assay for Flavivirus Antiviral Screening., PMID:29997331

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice., PMID:29976679

Molecular characterisation and phylogenetic analysis of dengue outbreak in Pasighat, Arunachal Pradesh, Northeast India., PMID:29735824

Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4., PMID:29593041

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852

Safe Staphylococcal Platform for the Development of Multivalent Nanoscale Vesicles against Viral Infections., PMID:29253342

A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3., PMID:28631593

Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis., PMID:28174309

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies., PMID:27301568

Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand., PMID:27265466

Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine., PMID:27223692

Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection., PMID:27185081

Characterization of the 2013 dengue epidemic in Myanmar with dengue virus 1 as the dominant serotype., PMID:27154331

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-DENV-2 Envelope protein E Polyclonal Antibody [PVV19906]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only